Table 2 Global assessment of disease incidence
SES-CE mean (SD)a | 8,5 (6) |
|---|---|
Entero-MRI n (%) | |
Absence of inflammation: | 13 (41.9) |
Persistent active disease inflammation: Worsening of inflammation: Improvement of inflammation: | 16 (51.6) 13 (81.2) 1(6.2) |
Stricturing disease: | 1 (3,2) |
Fistulizing disease: | 1 (3.2) |
Laboratory test mean (SD) | |
Hb (g/dL) | 13 (14.3) |
ESR (mm) | 21 (19.8) |
C-RP (mg/dL) | 0.6 (1.7) |
Ferritin (µg/dL) | 81.2 (123.8) |
Fecal Calprotectin (µg/g) | 803.7 (1189.7) |
PCDAI mean (SD)b | 7.5 (16.1) |
Clinical assessment score n (%) | |
Remission | 22 (70.9) |
Mild | 6 (19.4) |
Moderate | 4 (12.9) |
Severe | 0 |
Patient self-perception of disease n (%) | |
Feeling better | 11 (35.5) |
Feeling worse | 6 (19.3) |
Feeling the same | 14 45.2) |
IMPACT IIIcmean (SD) | 73.2 (13.1) |
PROMIS® T scores mean (SD) | |
Global health Depression | 43.2 (7.9) 51.1 (12.7) |
Anxiety | 50.4 (9.1) |
Meaning and purpose | 40.1 (8.1) |
Pain | 47.3 (12.6) |
Cognitive function | 46.7 (6.2) |
Life satisfaction | 44.1 (10.2) |
Peer relationship | 50.6 (9.5) |
Physical activity | 43.0 (7.2) |
Fatigue | 52.4 (12.1) |